1207175-15-2

Usage

Uses

Used in Pharmaceutical Industry:
2-methyl-2-propanyl 1-(aminomethyl)-3,4-dihydro-2(1H)-isoquinolinecarboxylate is used as a reagent for the preparation of praziquantel and its analogs. These compounds are known for their antischistosomal properties, making them valuable in the treatment of schistosomiasis, a parasitic disease that affects millions of people worldwide.
The compound's role in the synthesis of praziquantel and its analogs is crucial, as it contributes to the development of effective drugs that can combat the harmful effects of schistosomiasis. By facilitating the production of these antischistosomal agents, 2-methyl-2-propanyl 1-(aminomethyl)-3,4-dihydro-2(1H)-isoquinolinecarboxylate plays a significant part in the pharmaceutical industry's efforts to address global health challenges.

Upstream product

• 3230-65-7 3,4-dihydroisoquinoline 
• 1118640-91-7 (±)-tert-butyl 1-cyano-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 138350-92-2 tert-butyl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate 
• 64-04-0 phenethylamine 
• 88422-83-7 2-(3,4-dihydro-1-isoquinolinylmethyl)-1H-isoindole-1,3(2H)-dione 
• 310451-86-6 2-(1,2,3,4-tetrahydro-1-isoquinolinylmethyl)-1H-isoindole-1,3(2H)-dione 
• 88422-74-6 2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-(2-phenylethyl)acetamide 

Downstream Products

• 447450-46-6 C₁₇H₂₀N₂O₂S 
• 1357104-08-5 C₁₈H₁₇F₃N₂O 
• 1357104-09-6 C₁₈H₂₆N₂O 
• 1181230-06-7 2-tosyl-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one 
• 100650-29-1 2-(cyclohexanecarbonyl)-6,7-dihydro-1H-pyrazino[2,1-a]isoquinoline-3,4(2H,11bH)-dione 
• 1357104-13-2 2-tosyl-6,7-dihydro-1H-pyrazino[2,1-a]isoquinoline-3,4(2H,11bH)-dione 
• 1357104-14-3 2-(4-(trifluoromethyl)benzoyl)-6,7-dihydro-1H-pyrazino[2,1-a]isoquinoline-3,4(2H,11bH)-dione 
• 1357104-15-4 2-(2-cyclohexylacetyl)-6,7-dihydro-1H-pyrazino[2,1-a]isoquinoline-3,4(2H,11bH)-dione 
• 79848-93-4 N-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)cyclohexanecarboxylic acid amide 
• 55268-74-1 2-cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one 
• 1357104-00-7 C₂₃H₂₅F₃N₂O₃ 
• 1357103-95-7 C₂₂H₂₈N₂O₄S 
• 1357104-01-8 C₂₃H₃₄N₂O₃ 
• 1357103-92-4 t-butyl 1-(cyclohexanecarboxamidomethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AND USE THEREOF

Disclosed are compounds of formula (I) below or pharmaceutically acceptable salts thereof: in which each of variables R1-R6, L, m, and n is defined herein. Also disclosed are a method for treating an opioid receptor-associated condit

HETEROCYCLIC COMPOUNDS AND USE THEREOF

Disclosed are compounds of formula (I) below or pharmaceutically acceptable salts thereof:in which each of variables R 1 -R 6 , L, m, and n is defined herein. Also disclosed are a method for treating an opioid receptor-associated condition with a compound

DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS

A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.

DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS

A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keapl-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.

Synthesis of new praziquantel analogues: Potential candidates for the treatment of schistosomiasis

An efficient synthesis of antischistosomal drug praziquantel and analogues was achieved and the synthetic route designed was to afford structurally diverse analogues for better structure-activity relationship understanding. Total of nineteen PZQ analogues with structural variations at amide, piperazine and aromatic moieties have been synthesized and fully characterized. Among all the new analogues tested for antischistosomal activity, one dimethoxy tetrahydroisoquinoline analogue and two tetrahydro-β-carboline analogues exhibited moderate activity against adult Schistosoma mansoni. Tetrahydro-β-carboline analogues showed moderate activity whereas the presence of p-trifluoromethylbenzoyl and p-toluenesulphonyl moieties resulted in complete suppression of antischistosomal activity.